GLP1R and obesity disorder: By contrast, the consistent benefits observed in STEP-HFpEF [14,15] and SUMMIT [35] underscore the therapeutic potential of GLP-1 receptor agonists in obesity-related HFpEF and highlight the need for future trials to explore their role across broader HF phenotypes.